February 15, 2018
Rose
Digital diabetes care company Glooko announced today that its Mobile Insulin Dosing System (MIDS) — an app-driven tool that recommends insulin dose adjustments using data collected directly from a patient’s blood glucose meter — has been cleared by the FDA.
from MobiHealthNews http://ift.tt/2HgUzri
February 15, 2018
Rose
MobiHealthNews
No comments
Related Posts:
Digital health briefs: Easing pain with VR, digital assistants for runners, more Propeller funding- A third patent filing shows blood pressure monitoring on Apple's radar
- Glooko launches diabetes analytics platform
- Biological tissue sensor startup Sensome rakes in $5.4M in funding
- Medidata acquires Shyft for $195M, establishes unified trial, commercialization data platform
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment